Cargando…
Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial
OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose during lumpectomy, can effectively replace postoperative whole breast external beam radiotherapy for early breast cancer. DESIGN: Prospective, open label, randomised controlled clinical trial. SETTIN...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/ https://www.ncbi.nlm.nih.gov/pubmed/32816842 http://dx.doi.org/10.1136/bmj.m2836 |
_version_ | 1783583863480516608 |
---|---|
author | Vaidya, Jayant S Bulsara, Max Baum, Michael Wenz, Frederik Massarut, Samuele Pigorsch, Steffi Alvarado, Michael Douek, Michael Saunders, Christobel Flyger, Henrik L Eiermann, Wolfgang Brew-Graves, Chris Williams, Norman R Potyka, Ingrid Roberts, Nicholas Bernstein, Marcelle Brown, Douglas Sperk, Elena Laws, Siobhan Sütterlin, Marc Corica, Tammy Lundgren, Steinar Holmes, Dennis Vinante, Lorenzo Bozza, Fernando Pazos, Montserrat Le Blanc-Onfroy, Magali Gruber, Günther Polkowski, Wojciech Dedes, Konstantin J Niewald, Marcus Blohmer, Jens McCready, David Hoefer, Richard Kelemen, Pond Petralia, Gloria Falzon, Mary Joseph, David J Tobias, Jeffrey S |
author_facet | Vaidya, Jayant S Bulsara, Max Baum, Michael Wenz, Frederik Massarut, Samuele Pigorsch, Steffi Alvarado, Michael Douek, Michael Saunders, Christobel Flyger, Henrik L Eiermann, Wolfgang Brew-Graves, Chris Williams, Norman R Potyka, Ingrid Roberts, Nicholas Bernstein, Marcelle Brown, Douglas Sperk, Elena Laws, Siobhan Sütterlin, Marc Corica, Tammy Lundgren, Steinar Holmes, Dennis Vinante, Lorenzo Bozza, Fernando Pazos, Montserrat Le Blanc-Onfroy, Magali Gruber, Günther Polkowski, Wojciech Dedes, Konstantin J Niewald, Marcus Blohmer, Jens McCready, David Hoefer, Richard Kelemen, Pond Petralia, Gloria Falzon, Mary Joseph, David J Tobias, Jeffrey S |
author_sort | Vaidya, Jayant S |
collection | PubMed |
description | OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose during lumpectomy, can effectively replace postoperative whole breast external beam radiotherapy for early breast cancer. DESIGN: Prospective, open label, randomised controlled clinical trial. SETTING: 32 centres in 10 countries in the United Kingdom, Europe, Australia, the United States, and Canada. PARTICIPANTS: 2298 women aged 45 years and older with invasive ductal carcinoma up to 3.5 cm in size, cN0-N1, eligible for breast conservation and randomised before lumpectomy (1:1 ratio, blocks stratified by centre) to either risk adapted targeted intraoperative radiotherapy (TARGIT-IORT) or external beam radiotherapy (EBRT). INTERVENTIONS: Random allocation was to the EBRT arm, which consisted of a standard daily fractionated course (three to six weeks) of whole breast radiotherapy, or the TARGIT-IORT arm. TARGIT-IORT was given immediately after lumpectomy under the same anaesthetic and was the only radiotherapy for most patients (around 80%). TARGIT-IORT was supplemented by EBRT when postoperative histopathology found unsuspected higher risk factors (around 20% of patients). MAIN OUTCOME MEASURES: Non-inferiority with a margin of 2.5% for the absolute difference between the five year local recurrence rates of the two arms, and long term survival outcomes. RESULTS: Between 24 March 2000 and 25 June 2012, 1140 patients were randomised to TARGIT-IORT and 1158 to EBRT. TARGIT-IORT was non-inferior to EBRT: the local recurrence risk at five year complete follow-up was 2.11% for TARGIT-IORT compared with 0.95% for EBRT (difference 1.16%, 90% confidence interval 0.32 to 1.99). In the first five years, 13 additional local recurrences were reported (24/1140 v 11/1158) but 14 fewer deaths (42/1140 v 56/1158) for TARGIT-IORT compared with EBRT. With long term follow-up (median 8.6 years, maximum 18.90 years, interquartile range 7.0-10.6) no statistically significant difference was found for local recurrence-free survival (hazard ratio 1.13, 95% confidence interval 0.91 to 1.41, P=0.28), mastectomy-free survival (0.96, 0.78 to 1.19, P=0.82), distant disease-free survival (0.88, 0.69 to 1.12, P=0.30), overall survival (0.82, 0.63 to 1.05, P=0.13), and breast cancer mortality (1.12, 0.63 to 1.28, P=0.54). Mortality from other causes was significantly lower (0.59, 0.40 to 0.86, P=0.005). CONCLUSION: For patients with early breast cancer who met our trial selection criteria, risk adapted immediate single dose TARGIT-IORT during lumpectomy was an effective alternative to EBRT, with comparable long term efficacy for cancer control and lower non-breast cancer mortality. TARGIT-IORT should be discussed with eligible patients when breast conserving surgery is planned. TRIAL REGISTRATION: ISRCTN34086741, NCT00983684. |
format | Online Article Text |
id | pubmed-7500441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75004412020-09-28 Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial Vaidya, Jayant S Bulsara, Max Baum, Michael Wenz, Frederik Massarut, Samuele Pigorsch, Steffi Alvarado, Michael Douek, Michael Saunders, Christobel Flyger, Henrik L Eiermann, Wolfgang Brew-Graves, Chris Williams, Norman R Potyka, Ingrid Roberts, Nicholas Bernstein, Marcelle Brown, Douglas Sperk, Elena Laws, Siobhan Sütterlin, Marc Corica, Tammy Lundgren, Steinar Holmes, Dennis Vinante, Lorenzo Bozza, Fernando Pazos, Montserrat Le Blanc-Onfroy, Magali Gruber, Günther Polkowski, Wojciech Dedes, Konstantin J Niewald, Marcus Blohmer, Jens McCready, David Hoefer, Richard Kelemen, Pond Petralia, Gloria Falzon, Mary Joseph, David J Tobias, Jeffrey S BMJ Research OBJECTIVE: To determine whether risk adapted intraoperative radiotherapy, delivered as a single dose during lumpectomy, can effectively replace postoperative whole breast external beam radiotherapy for early breast cancer. DESIGN: Prospective, open label, randomised controlled clinical trial. SETTING: 32 centres in 10 countries in the United Kingdom, Europe, Australia, the United States, and Canada. PARTICIPANTS: 2298 women aged 45 years and older with invasive ductal carcinoma up to 3.5 cm in size, cN0-N1, eligible for breast conservation and randomised before lumpectomy (1:1 ratio, blocks stratified by centre) to either risk adapted targeted intraoperative radiotherapy (TARGIT-IORT) or external beam radiotherapy (EBRT). INTERVENTIONS: Random allocation was to the EBRT arm, which consisted of a standard daily fractionated course (three to six weeks) of whole breast radiotherapy, or the TARGIT-IORT arm. TARGIT-IORT was given immediately after lumpectomy under the same anaesthetic and was the only radiotherapy for most patients (around 80%). TARGIT-IORT was supplemented by EBRT when postoperative histopathology found unsuspected higher risk factors (around 20% of patients). MAIN OUTCOME MEASURES: Non-inferiority with a margin of 2.5% for the absolute difference between the five year local recurrence rates of the two arms, and long term survival outcomes. RESULTS: Between 24 March 2000 and 25 June 2012, 1140 patients were randomised to TARGIT-IORT and 1158 to EBRT. TARGIT-IORT was non-inferior to EBRT: the local recurrence risk at five year complete follow-up was 2.11% for TARGIT-IORT compared with 0.95% for EBRT (difference 1.16%, 90% confidence interval 0.32 to 1.99). In the first five years, 13 additional local recurrences were reported (24/1140 v 11/1158) but 14 fewer deaths (42/1140 v 56/1158) for TARGIT-IORT compared with EBRT. With long term follow-up (median 8.6 years, maximum 18.90 years, interquartile range 7.0-10.6) no statistically significant difference was found for local recurrence-free survival (hazard ratio 1.13, 95% confidence interval 0.91 to 1.41, P=0.28), mastectomy-free survival (0.96, 0.78 to 1.19, P=0.82), distant disease-free survival (0.88, 0.69 to 1.12, P=0.30), overall survival (0.82, 0.63 to 1.05, P=0.13), and breast cancer mortality (1.12, 0.63 to 1.28, P=0.54). Mortality from other causes was significantly lower (0.59, 0.40 to 0.86, P=0.005). CONCLUSION: For patients with early breast cancer who met our trial selection criteria, risk adapted immediate single dose TARGIT-IORT during lumpectomy was an effective alternative to EBRT, with comparable long term efficacy for cancer control and lower non-breast cancer mortality. TARGIT-IORT should be discussed with eligible patients when breast conserving surgery is planned. TRIAL REGISTRATION: ISRCTN34086741, NCT00983684. BMJ Publishing Group Ltd. 2020-08-19 /pmc/articles/PMC7500441/ /pubmed/32816842 http://dx.doi.org/10.1136/bmj.m2836 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Vaidya, Jayant S Bulsara, Max Baum, Michael Wenz, Frederik Massarut, Samuele Pigorsch, Steffi Alvarado, Michael Douek, Michael Saunders, Christobel Flyger, Henrik L Eiermann, Wolfgang Brew-Graves, Chris Williams, Norman R Potyka, Ingrid Roberts, Nicholas Bernstein, Marcelle Brown, Douglas Sperk, Elena Laws, Siobhan Sütterlin, Marc Corica, Tammy Lundgren, Steinar Holmes, Dennis Vinante, Lorenzo Bozza, Fernando Pazos, Montserrat Le Blanc-Onfroy, Magali Gruber, Günther Polkowski, Wojciech Dedes, Konstantin J Niewald, Marcus Blohmer, Jens McCready, David Hoefer, Richard Kelemen, Pond Petralia, Gloria Falzon, Mary Joseph, David J Tobias, Jeffrey S Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial |
title | Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial |
title_full | Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial |
title_fullStr | Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial |
title_full_unstemmed | Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial |
title_short | Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial |
title_sort | long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (targit-iort) for early breast cancer: targit-a randomised clinical trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500441/ https://www.ncbi.nlm.nih.gov/pubmed/32816842 http://dx.doi.org/10.1136/bmj.m2836 |
work_keys_str_mv | AT vaidyajayants longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT bulsaramax longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT baummichael longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT wenzfrederik longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT massarutsamuele longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT pigorschsteffi longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT alvaradomichael longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT douekmichael longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT saunderschristobel longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT flygerhenrikl longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT eiermannwolfgang longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT brewgraveschris longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT williamsnormanr longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT potykaingrid longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT robertsnicholas longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT bernsteinmarcelle longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT browndouglas longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT sperkelena longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT lawssiobhan longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT sutterlinmarc longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT coricatammy longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT lundgrensteinar longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT holmesdennis longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT vinantelorenzo longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT bozzafernando longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT pazosmontserrat longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT leblanconfroymagali longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT grubergunther longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT polkowskiwojciech longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT dedeskonstantinj longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT niewaldmarcus longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT blohmerjens longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT mccreadydavid longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT hoeferrichard longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT kelemenpond longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT petraliagloria longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT falzonmary longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT josephdavidj longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial AT tobiasjeffreys longtermsurvivalandlocalcontroloutcomesfromsingledosetargetedintraoperativeradiotherapyduringlumpectomytargitiortforearlybreastcancertargitarandomisedclinicaltrial |